Last updated on November 2018

A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).

Clinical Study Identifier: NCT03105128

Contact Investigators or Research Sites near you

Start Over

ABBVIE CALL CENTER

Healthcare Institution /ID# 159499
Grodno, Belarus
  Connect »